Phase 2b Open‑Label Repeat Kidney Biopsy Study
Sponsor ID
417-201-00060
Clinicaltrials.gov ID
EudraCT ID
N/A
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
N/A
Active, Not Recruiting
Sponsor ID
417-201-00060
Study Summary
Assess impact of sibeprenlimab on IgA deposition and other histological endpoints in kidney tissue at Week 52 relative to baseline
Inclusion and Exclusion Criteria
Inclusion Criteria
- 1. Participants must be at least 18 years of age or older at the time of signing the informed consent/assent.
- 2. Source-verified kidney biopsy confirmed diagnosis of IgAN.
Exclusion Criteria
- 1. Participants who are breast-feeding and/or who have a positive pregnancy test result prior to receiving sibeprenlimab.
- 2. Participant has coexisting chronic kidney disease, other than IgAN.
Inclusion and Exclusion Criteria
Inclusion Criteria:
- Participants must be at least 18 years of age or older at the time of signing the informed consent/assent.
- Source-verified kidney biopsy confirmed diagnosis of IgAN.
- Participant has eGFR \> 45 mL/min/1.73 m2 using serum creatinine based on CKD-EPI 2021 equation. Serum creatinine assessments for the determination of eGFR should be taken when the participant is considered to be in a steady state without recent changes in volume status, medications that could impact the result (eg, nonsteroidal anti-inflammatory drugs \[NSAIDs\], aminoglycosides, trimethoprim, cimetidine, pyrimethamine, fenofibrate, or creatine supplements), or changes in dietary protein intake.
Exclusion Criteria:
- Participants who are breast-feeding and/or who have a positive pregnancy test result prior to receiving sibeprenlimab.
- Participant has coexisting chronic kidney disease, other than IgAN.
- Participant has a serum IgG value \<600 mg/dL at screening.
- Participant is currently receiving or has received within 24 weeks prior to the firstdose of sibeprenlimab, systemic corticosteroids or immunosuppression (note:
- topical, ophthalmic, rectal, intra-articular, inhaled corticosteroids are allowed).
- Participant has uncontrolled hypertension (defined as systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg).
- Participants who would be likely to require prohibited concomitant therapy during the trial.
Locations
Location
Status
Location
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Status
N/A
Location
Stanford University Medical Center
Stanford, California, United States, 94305
Status
N/A
Location
Colorado Kidney Care PC
Denver, Colorado, United States, 80220
Status
N/A
Location
Massachusetts General Hospital (MGH) Harvard
Boston, Massachusetts, United States, 21144
Status
N/A
Location
Dakota Dunes
Dakota Dunes, South Dakota, United States, 57409
Status
N/A
Location
Prolato Clinical Research Center
Houston, Texas, United States, 77054
Status
N/A
Showing {first} - {last} of {total} Results